Exhibit 99.1
BIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS
WARSAW, Ind., October 10, 2012 – Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2012.
| • | Initial close of the Trauma Acquisition was announced June 15, 2012; substantially completed |
| • | Net sales increased 6% (10% constant currency) worldwide to approximately $707 million |
| • | Net sales, excluding the Trauma Acquisition, increased 1% (4% constant currency) worldwide |
| • | Large Joint Reconstructive sales decreased 1% (grew 2% constant currency) worldwide, with 1% growth in the U.S. |
| • | S.E.T. sales increased 56% (59% constant currency) worldwide and increased 52% in the U.S. |
| • | Excluding the Trauma Acquisition, S.E.T. sales increased 8% (10% constant currency) and increased 11% in the U.S. |
| • | Initiated refinancing activities to reduce cost of overall debt capital structure |
First Quarter Financial Results
Net sales increased 6% during the first quarter of fiscal year 2013 to $707.4 million compared to net sales of $664.6 million during the first quarter of fiscal year 2012. Excluding the effect of foreign currency, net sales increased 10% during the first quarter. U.S. net sales increased 9% to $452.2 million during the first quarter, while Europe net sales decreased 4% (increased 9% constant currency) to $142.9 million and International (primarily Canada, South America, Mexico and the Pacific Rim) net sales increased 11% (14% constant currency) to $112.3 million.
Special items (pre-tax) for the fiscal first quarter totaled $122.7 million, including $74.7 million of non-cash amortization expense related to the 2007 Merger and $48.0 million of special items, primarily associated with the Trauma Acquisition and the Company’s stock-based compensation modification.
Reported operating income during the first quarter of fiscal year 2013 was $69.0 million compared to operating income of $72.7 million during the first quarter of fiscal year 2012. Excluding special items, adjusted operating income totaled $191.7 million during the first quarter of fiscal year 2013, compared to $182.3 million for the first quarter of fiscal year 2012.
Excluding special items, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) was $237.8 million, or 33.6% of net sales during the first quarter of fiscal year 2013, compared to $226.6 million, or 34.1% of net sales for the first quarter of fiscal year 2012.
Interest expense during the first quarter of fiscal year 2013 totaled $117.1 million compared to $125.4 million during the first quarter of the prior year, primarily due to lower average interest rates on our term loans.
Reported cash flow from operations totaled $85.5 million for the first quarter of fiscal year 2013, as compared to reported cash flow from operations of $123.1 million for the first quarter of fiscal year 2012. Free cash flow (operating cash flow of $85.5 million minus capital expenditures of $53.1 million) was $32.4 million, which reflected $62.5 million of cash interest paid in the quarter compared to free cash flow (operating cash flow of $123.1 million minus capital expenditures of $39.2 million) of $83.9 million during the first quarter of fiscal year 2012, which reflected $55.0 million of cash interest paid.
During the first quarter of fiscal year 2013, the Company utilized cash on hand of $280 million to fund the Trauma Acquisition. In addition, we initiated various debt refinancing activities during the quarter, which are expected to be completed during our fiscal second quarter of 2013. At August 31, 2012, reported gross debt was approximately $6.282 billion, and cash and cash equivalents, as defined in the Company’s Credit Agreement dated September 25, 2007, totaled $619.2 million, resulting in net debt of $5.663 billion, compared to $5.335 billion at May 31, 2012.
Biomet’s senior secured leverage ratio as of August 31, 2012 was 2.55 times the last twelve months (“LTM”) adjusted EBITDA, as defined by our credit agreement, compared to 2.70 times at May 31, 2012 and 4.01 times at May 31, 2008. The total (net debt) leverage ratio was 5.43 times LTM adjusted EBITDA at August 31, 2012, compared to 5.17 times at May 31, 2012 and 6.97 times at May 31, 2008.
Biomet’s President and Chief Executive Officer Jeffrey R. Binder stated, “Overall, I’m generally pleased with our results for the first quarter of fiscal year 2013. The completion of the trauma acquisition bolsters our S.E.T. product category to annualized sales in excess of $500 million in an attractive segment of the orthopaedic market. The team has executed well on the integration and our investment in building a great S.E.T. business is paying off. We did experience some deceleration in growth for our hip and knee business, but until others report their results we won’t know whether market growth has slowed or our growth has come back to market.”
The following table provides first quarter net sales performance by product category:
First Quarter Net Sales Performance | ||||||||||||||||
| (in millions, except percentages, unaudited) | ||||||||||||||||
| Worldwide Reported Quarter 1 - FY 2013 | Worldwide Reported Growth % | Worldwide CC Growth % | United States Growth % | |||||||||||||
Large Joint Reconstructive | $ | 393.0 | (1 | )% | 2 | % | 1 | % | ||||||||
Knees | (1 | )% | 2 | % | 1 | % | ||||||||||
Hips | (1 | )% | 2 | % | 1 | % | ||||||||||
Bone Cement and Other | (2 | )% | 4 | % | 6 | % | ||||||||||
Sports, Extremities, Trauma (S.E.T.) | 127.3 | 56 | % | 59 | % | 52 | % | |||||||||
Sports Medicine | 9 | % | 12 | % | 8 | % | ||||||||||
Extremities | 13 | % | 15 | % | 20 | % | ||||||||||
Trauma | 192 | % | 199 | % | 190 | % | ||||||||||
Spine & Bone Healing | 77.9 | 4 | % | 5 | % | 5 | % | |||||||||
Spine | 10 | % | 11 | % | 11 | % | ||||||||||
Bone Healing | (10 | )% | (9 | )% | (10 | )% | ||||||||||
Dental | 57.0 | (4 | )% | 1 | % | 4 | % | |||||||||
Other | 52.2 | 1 | % | 4 | % | 1 | % | |||||||||
|
|
|
|
|
|
|
| |||||||||
Net Sales | $ | 707.4 | 6 | % | 10 | % | 9 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Sports, Extremities, Trauma (S.E.T.) excluding Trauma Acquisition | 8 | % | 10 | % | 11 | % | ||||||||||
Trauma excluding Trauma Acquisition | (2 | )% | — | % | — | % | ||||||||||
Net Sales excluding Trauma Acquisition | 1 | % | 4 | % | 3 | % | ||||||||||
Large Joint Reconstructive sales decreased 1% (increased 2% constant currency) worldwide to $393.0 million and increased 1% in the U.S. during the first quarter of fiscal year 2013 compared to the first quarter of fiscal year 2012. Knee sales decreased 1% (increased 2% constant currency) worldwide during the first quarter and increased 1% in the U.S. Hip sales decreased 1% (increased 2% constant currency) worldwide during the first quarter and increased 1% in the U.S.
S.E.T. sales increased 56% (59% constant currency) worldwide to $127.3 million during the first quarter, and increased 52% in the U.S. Excluding the Trauma Acquisition, S.E.T. sales increased 8% (10% constant currency) worldwide and increased 11% in the U.S. Sports medicine sales increased 9% (12% constant currency) worldwide during the quarter and increased 8% in the U.S. Extremity sales grew 13% (15% constant currency) worldwide during the quarter, with a growth rate of 20% in the U.S. Trauma sales increased 192% (199% constant currency) worldwide during the quarter and increased 190% in the U.S. Trauma sales, excluding the Trauma Acquisition, decreased 2% (flat at constant currency) worldwide and were flat in the U.S.
Spine and Bone Healing (non-invasive trauma stimulation and bracing) sales increased 4% (5% constant currency) worldwide to $77.9 million during the first quarter and increased 5% in the U.S.
Dental sales decreased 4% (increased 1% constant currency) worldwide to $57.0 million and increased 4% in the U.S. during the first quarter.
Sales of Other products increased 1% (4% constant currency) worldwide to $52.2 million during the first quarter and increased 1% in the U.S.
About Biomet
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses large joint reconstructive products, including orthopedic joint replacement devices, and bone cements and accessories; sports medicine, extremities and trauma products, including internal and external orthopedic fixation devices; spine and bone healing products, including spine hardware, spinal stimulation devices, and orthobiologics, as well as electrical bone growth stimulators and softgoods and bracing; dental reconstructive products; and other products, including microfixation products and autologous therapies. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.
Contacts
For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer, at (574) 372-1687 or Barbara Goslee, Director, Investor Relations at (574) 372-1514.
Financial Schedule Presentation
The Company’s unaudited condensed consolidated financial statements as of and for the three months ended August 31, 2012 and 2011 and other financial data included in this press release have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles in the United States (except with respect to certain non-GAAP financial measures discussed below), and reflects purchase accounting adjustments related to the Merger referenced below and the Trauma Acquisition.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the success of the Company’s principal product lines; the results of the ongoing investigation by the United States Department of Justice; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Deferred Prosecution Agreement and Corporate Integrity Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the ability of the Company to successfully integrate the Trauma Acquisition; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; the impact of product liability litigation losses; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.
*Non-GAAP Financial Measures:
Management uses non-GAAP financial measures, such as net sales excluding the impact of foreign currency (constant currency), operating income as adjusted, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) as adjusted, net income as adjusted, gross profit as adjusted, selling, general and administrative expense as adjusted, research and development expense as adjusted, cash and cash equivalents (as defined by our credit agreement), net debt, senior secured leverage ratio, total leverage ratio , free cash flow, and unlevered free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in the press release.
The term “adjusted” or “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization, other (income) expense, and/or exclude certain expenses as defined by our credit agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business
optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the Company’s private equity owners, certain severance charges, purchase accounting costs, stock-based compensation, litigation costs, and other related charges.
These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP in the United States. Biomet management believes that these non-GAAP financial measures provide useful information to investors; however, this additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.
Non-GAAP Reconciliation
A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website: www.biomet.com
Reclassifications
Certain prior period amounts have been reclassified to conform to the current presentation. Such reclassifications were limited to net sales information by product categories. The current presentation aligns with how the Company presently reports sales and markets its products.
The Merger
Biomet, Inc. finalized the merger with LVB Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LVB Acquisition, Inc., which we refer to in this press release as the “Merger”, on September 25, 2007. LVB Acquisition, Inc. is indirectly owned by investment partnerships directly or indirectly advised or managed by The Blackstone Group, Goldman Sachs & Co., Kohlberg Kravis Roberts & Co. and TPG Global
Trauma Acquisition
On May 24, 2012, DePuy Orthopaedics, Inc. accepted the Company’s binding offer to purchase certain assets representing substantially all of DePuy’s worldwide trauma business (“Trauma Acquisition”), which involves researching, developing, manufacturing, marketing, distributing and selling products to treat certain bone fractures or deformities in the human body, including certain intellectual property assets, and to assume certain liabilities, for approximately $280.0 million in cash. On June 15, 2012, the Company announced the initial closing of the transaction, acquiring DePuy’s trauma operations in the U.S., the United Kingdom, Australia, New Zealand and Japan, as well as DePuy’s trauma manufacturing operations in Le Locle, Switzerland. On July 13, 2012, the Company closed in Belgium, France, Germany, Luxembourg, The Netherlands, Portugal, South Africa, Spain, Ireland, Italy and the Switzerland non-manufacturing unit. In August, the Company closed on ten additional countries including China. Subsequent closings for the remaining countries will occur on a staggered basis and, in general, are expected to be completed within six months of the initial closing. DePuy affiliates will serve as the Company’s interim distributors in these countries until these operations are fully transitioned to the Company. The Company acquired the DePuy worldwide trauma business to strengthen its trauma business and to continue to build a stronger presence in the global trauma market.
Biomet, Inc.
Product Net Sales
Three Month Period Ended August 31, 2012 and 2011
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | Reported Growth % | Constant Currency* Growth % | |||||||||||||
Large Joint Reconstructive | $ | 393.0 | $ | 397.0 | (1 | )% | 2 | % | ||||||||
Sports, Extremities, Trauma (S.E.T.) | 127.3 | 81.8 | 56 | % | 59 | % | ||||||||||
Spine & Bone Healing | 77.9 | 74.6 | 4 | % | 5 | % | ||||||||||
Dental | 57.0 | 59.3 | (4 | )% | 1 | % | ||||||||||
Other | 52.2 | 51.9 | 1 | % | 4 | % | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Net Sales | $ | 707.4 | $ | 664.6 | 6 | % | 10 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Sports, Extremities, Trauma (S.E.T.) excluding Trauma Acquisition | 88.5 | 81.8 | 8 | % | 10 | % | ||||||||||
Net Sales, excluding Trauma Acquisition | 668.6 | 664.6 | 1 | % | 4 | % | ||||||||||
| Three Months Ended August 31, 2012 Net Sales Growth As Reported | Currency Impact* | Three Months Ended August 31, 2012 Net Sales Growth in Local Currencies* | ||||||||||
Large Joint Reconstructive | (1 | )% | 3 | % | 2 | % | ||||||
Knees | (1 | )% | 3 | % | 2 | % | ||||||
Hips | (1 | )% | 3 | % | 2 | % | ||||||
Bone Cement and Other | (2 | )% | 6 | % | 4 | % | ||||||
Sports, Extremities, Trauma (S.E.T.) | 56 | % | 3 | % | 59 | % | ||||||
Sports Medicine | 9 | % | 3 | % | 12 | % | ||||||
Extremities | 13 | % | 2 | % | 15 | % | ||||||
Trauma | 192 | % | 7 | % | 199 | % | ||||||
Spine & Bone Healing | 4 | % | 1 | % | 5 | % | ||||||
Spine | 10 | % | �� | 1 | % | 11 | % | |||||
Bone Healing | (10 | )% | 1 | % | (9 | )% | ||||||
Dental | (4 | )% | 5 | % | 1 | % | ||||||
Other | 1 | % | 3 | % | 4 | % | ||||||
|
|
|
|
|
| |||||||
Net Sales | 6 | % | 4 | % | 10 | % | ||||||
|
|
|
|
|
| |||||||
Sports, Extremities, Trauma (S.E.T.) excluding Trauma Acquisition | 8 | % | 2 | % | 10 | % | ||||||
Trauma excluding Trauma Acquisition | (2 | )% | 2 | % | — | % | ||||||
Net Sales excluding Trauma Acquisition | 1 | % | 3 | % | 4 | % | ||||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Geographic Net Sales
Three Month Period Ended August 31, 2012 and 2011
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | Reported Growth % | Constant Currency* Growth % | |||||||||||||
Geographic Sales: | ||||||||||||||||
United States | $ | 452.2 | $ | 414.7 | 9 | % | 9 | % | ||||||||
Europe | 142.9 | 148.5 | (4 | )% | 9 | % | ||||||||||
International | 112.3 | 101.4 | 11 | % | 14 | % | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Net Sales | $ | 707.4 | $ | 664.6 | 6 | % | 10 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
| Three Months Ended August 31, 2012 Net Sales Growth As Reported | Currency Impact* | Three Months Ended August 31, 2012 Net Sales Growth Local Currencies* | ||||||||||
United States | 9 | % | — | % | 9 | % | ||||||
Europe | (4 | )% | 13 | % | 9 | % | ||||||
International | 11 | % | 3 | % | 14 | % | ||||||
|
|
|
|
|
| |||||||
Total | 6 | % | 4 | % | 10 | % | ||||||
|
|
|
|
|
| |||||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Geographic Net Sales excluding Trauma Acquisition
Three Month Period Ended August 31, 2012 and 2011
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | Reported Growth % | Constant Currency* Growth % | |||||||||||||
Geographic Sales excluding Trauma Acquisition: | ||||||||||||||||
United States | $ | 428.7 | $ | 414.7 | 3 | % | 3 | % | ||||||||
Europe | 134.1 | 148.5 | (10 | )% | 2 | % | ||||||||||
International | 105.8 | 101.4 | 4 | % | 8 | % | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Net Sales | $ | 668.6 | $ | 664.6 | 1 | % | 4 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
| Three Months Ended August 31, 2012 Net Sales Growth As Reported | Currency Impact* | Three Months Ended August 31, 2012 Net Sales Growth Local Currencies* | ||||||||||
United States | 3 | % | — | % | 3 | % | ||||||
Europe | (10 | )% | 12 | % | 2 | % | ||||||
International | 4 | % | 4 | % | 8 | % | ||||||
|
|
|
|
|
| |||||||
Total | 1 | % | 3 | % | 4 | % | ||||||
|
|
|
|
|
| |||||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
As Reported Consolidated Statements of Operations
(in millions, except percentages, unaudited)
| Three Months Ended | Three Months Ended | |||||||
| August 31, 2012 | August 31, 2011 | |||||||
Net sales | $ | 707.4 | $ | 664.6 | ||||
Cost of sales | 228.1 | 215.3 | ||||||
|
|
|
| |||||
Gross profit | 479.3 | 449.3 | ||||||
Gross profit percentage | 67.8 | % | 67.6 | % | ||||
Selling, general and administrative expense | 296.1 | 261.6 | ||||||
Research and development expense | 35.8 | 32.0 | ||||||
Amortization | 78.4 | 83.0 | ||||||
|
|
|
| |||||
Operating income | 69.0 | 72.7 | ||||||
Interest expense | 117.1 | 125.4 | ||||||
Other (income) expense | 37.5 | 7.2 | ||||||
|
|
|
| |||||
Loss before income taxes | (85.6 | ) | (59.9 | ) | ||||
Benefit from income taxes | (54.1 | ) | (20.7 | ) | ||||
|
|
|
| |||||
Tax rate | 63.2 | % | 34.6 | % | ||||
Net loss | $ | (31.5 | ) | $ | (39.2 | ) | ||
|
|
|
| |||||
Percentage of Net Sales | -4.5 | % | -5.9 | % | ||||
Biomet, Inc.
Other Financial Information
Reconciliation of Operating Income, as reported to Operating Income, as adjusted*
(in millions, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Operating income, as reported | $ | 69.0 | $ | 72.7 | ||||
Purchase accounting depreciation | — | 4.6 | ||||||
Purchase accounting amortization | 74.7 | 80.9 | ||||||
Stock-based compensation expense | 19.1 | 4.7 | ||||||
Litigation settlements and reserves and other legal fees | 4.6 | 1.0 | ||||||
Trauma acquisition costs | 6.9 | — | ||||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) | 6.8 | 16.4 | ||||||
Inventory and property, plant and equipment step-up related to the trauma acquisition | (0.1 | ) | — | |||||
Excess and obsolete inventory expense related to the trauma acquisition | 8.1 | — | ||||||
Sponsor fee | 2.6 | 2.0 | ||||||
|
|
|
| |||||
Total items (pre-tax) excluded per our credit agreement | 122.7 | 109.6 | ||||||
|
|
|
| |||||
Operating income, as adjusted* | $ | 191.7 | $ | 182.3 | ||||
|
|
|
| |||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
Reconciliation of Operating Income, as reported to EBITDA, as adjusted*
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Operating Income, as reported | $ | 69.0 | $ | 72.7 | ||||
Depreciation | 42.1 | 46.8 | ||||||
Amortization | 78.4 | 83.0 | ||||||
Special items adjustments | ||||||||
Stock-based compensation expense | 19.1 | 4.7 | ||||||
Litigation settlements and reserves and other legal fees | 4.6 | 1.0 | ||||||
Trauma acquisition costs | 6.9 | — | ||||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) | 6.8 | 16.4 | ||||||
Inventory and property, plant and equipment step-up related to the trauma acquisition | 0.2 | — | ||||||
Excess and obsolete inventory expense related to the trauma acquisition | 8.1 | — | ||||||
Sponsor fee | 2.6 | 2.0 | ||||||
|
|
|
| |||||
EBITDA, as adjusted* | $ | 237.8 | $ | 226.6 | ||||
|
|
|
| |||||
Net sales | $ | 707.4 | $ | 664.6 | ||||
EBITDA percentage, as adjusted* | 33.6 | % | 34.1 | % | ||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
Reconciliation of Net Loss, as reported to Net Income, as adjusted*
(in millions, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Net loss, as reported | $ | (31.5 | ) | $ | (39.2 | ) | ||
Purchase accounting depreciation | — | 4.6 | ||||||
Purchase accounting amortization | 74.7 | 80.9 | ||||||
Stock-based compensation expense | 19.1 | 4.7 | ||||||
Litigation settlements and reserves and other legal fees | 4.6 | 1.0 | ||||||
Trauma acquisition costs | 6.9 | — | ||||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) | 6.8 | 16.4 | ||||||
Inventory and property, plant and equipment step-up related to the trauma acquisition | (0.1 | ) | — | |||||
Excess and obsolete inventory expense related to the trauma acquisition | 8.1 | — | ||||||
Sponsor fee | 2.6 | 2.0 | ||||||
Tax effect on special and purchase accounting items** | (63.7 | ) | (41.8 | ) | ||||
|
|
|
| |||||
Net income, as adjusted* | $ | 27.5 | $ | 28.6 | ||||
|
|
|
| |||||
| * | See Non-GAAP Financial Measures Disclosure |
| ** | The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred |
Biomet, Inc.
Other Financial Information
Reconciliation of Gross Profit, as reported to Gross Profit, as adjusted*
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Gross profit, as reported | $ | 479.3 | $ | 449.3 | ||||
Purchase accounting depreciation | — | 4.6 | ||||||
Stock-based compensation expense | 1.5 | 0.3 | ||||||
Litigation settlements and reserves and other legal fees | 3.4 | — | ||||||
Trauma acquisition costs | 1.4 | — | ||||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) | 3.6 | 10.2 | ||||||
Inventory and property, plant and equipment step-up related to the trauma acquisition | (0.1 | ) | — | |||||
Excess and obsolete inventory expense related to the trauma acquisition | 8.1 | — | ||||||
|
|
|
| |||||
Gross profit, as adjusted* | $ | 497.2 | $ | 464.4 | ||||
|
|
|
| |||||
Net sales | $ | 707.4 | $ | 664.6 | ||||
Gross profit percentage, as reported | 67.8 | % | 67.6 | % | ||||
Gross profit percentage, as adjusted* | 70.3 | % | 69.9 | % | ||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
Reconciliation of Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense,
as adjusted*
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Selling, general and administrative expense, as reported | $ | 296.1 | $ | 261.6 | ||||
Stock-based compensation expense | (14.7 | ) | (3.9 | ) | ||||
Litigation settlements and reserves and other legal fees | (1.2 | ) | (1.0 | ) | ||||
Trauma acquisition costs | (5.5 | ) | — | |||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, and other related costs) | (3.2 | ) | (6.1 | ) | ||||
Sponsor fee | (2.6 | ) | (2.0 | ) | ||||
|
|
|
| |||||
Selling, general and administrative expense, as adjusted* | $ | 268.9 | $ | 248.6 | ||||
|
|
|
| |||||
Net sales | $ | 707.4 | $ | 664.6 | ||||
SG&A as a percentage of net sales, as reported | 41.9 | % | 39.4 | % | ||||
SG&A as a percentage of net sales, as adjusted* | 38.0 | % | 37.4 | % | ||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
Reconciliation of Research and Development Expense, as reported to Research and Development Expense, as adjusted*
(in millions, except percentages, unaudited)
| Three Months Ended August 31, 2012 | Three Months Ended August 31, 2011 | |||||||
Research and development expense, as reported | $ | 35.8 | $ | 32.0 | ||||
Stock-based compensation expense | (2.9 | ) | (0.5 | ) | ||||
Operational restructuring and consulting expenses related to operational initiatives (severance, and other related costs) | — | (0.1 | ) | |||||
|
|
|
| |||||
Research and development expense, as adjusted* | $ | 32.9 | $ | 31.4 | ||||
|
|
|
| |||||
Net sales | $ | 707.4 | $ | 664.6 | ||||
R&D as a percentage of net sales, as reported | 5.1 | % | 4.8 | % | ||||
R&D as a percentage of net sales, as adjusted* | 4.7 | % | 4.7 | % | ||||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Condensed Consolidated Balance Sheets
(in millions, unaudited)
| (Preliminary) August 31, 2012 | May 31, 2012 | |||||||
Assets | ||||||||
Cash and cash equivalents | $ | 619.2 | $ | 492.4 | ||||
Accounts receivable, net | 487.7 | 491.6 | ||||||
Short-term investments | 2.5 | 2.5 | ||||||
Inventories | 650.2 | 543.2 | ||||||
Current deferred income taxes | 53.4 | 52.5 | ||||||
Prepaid expenses and other | 150.6 | 129.1 | ||||||
Property, plant and equipment, net | 668.2 | 593.6 | ||||||
Intangible assets, net | 3,940.9 | 3,930.4 | ||||||
Goodwill | 4,182.2 | 4,114.4 | ||||||
Other assets | 96.3 | 70.7 | ||||||
|
|
|
| |||||
Total Assets | $ | 10,851.2 | $ | 10,420.4 | ||||
|
|
|
| |||||
Liabilities and Shareholder’s Equity | ||||||||
Current liabilities, excluding debt | $ | 484.8 | $ | 474.9 | ||||
Current portion of long-term debt | 35.7 | 35.6 | ||||||
Long-term debt, net of current portion | 6,246.2 | 5,792.2 | ||||||
Deferred income taxes, long-term | 1,192.4 | 1,257.8 | ||||||
Other long-term liabilities | 200.5 | 177.8 | ||||||
Shareholder’s equity | 2,691.6 | 2,682.1 | ||||||
|
|
|
| |||||
Total Liabilities and Shareholder’s Equity | $ | 10,851.2 | $ | 10,420.4 | ||||
|
|
|
| |||||
Net Debt(a)* | $ | 5,662.7 | $ | 5,335.4 | ||||
| (a) | Net debt is the sum of total debt less cash and cash equivalents, as defined by the credit agreement. |
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
Reconciliation of Senior Secured Leverage Ratio and Total Leverage Ratio*
(in millions, except ratios, unaudited)
| August 31, 2012 | May 31, 2008 | |||||||
Senior Secured Debt: | ||||||||
USD Term Loan B | $ | 2,228.9 | $ | 2,328.3 | ||||
EUR Term Loan B | 1,044.4 | 1,355.2 | ||||||
Asset Based Revolver | — | — | ||||||
Cash Flow Revolvers | — | — | ||||||
|
|
|
| |||||
Consolidated Senior Secured Debt | 3,273.3 | A | 3,683.5 | E | ||||
Senior Notes | 3,005.5 | 2,570.7 | ||||||
European Facilities | 3.1 | 46.6 | ||||||
|
|
|
| |||||
Consolidated Total Debt | 6,281.9 | 6,300.8 | ||||||
Cash and Cash Equivalents* ** | (619.2 | ) B | (127.6 | ) F | ||||
|
|
|
| |||||
Net Debt* | $ | 5,662.7 | C | $ | 6,173.2 | G | ||
|
|
|
| |||||
LTM Adjusted EBITDA | ||||||||
Quarter 2 Fiscal 2012 Adjusted EBITDA | 266.3 | |||||||
Quarter 3 Fiscal 2012 Adjusted EBITDA | 260.5 | |||||||
Quarter 4 Fiscal 2012 Adjusted EBITDA | 277.7 | |||||||
Quarter 1 Fiscal 2013 Adjusted EBITDA | 237.8 | |||||||
“Run Rate” Cost Savings** | — | |||||||
|
| |||||||
Quarter 1 2013 LTM Adjusted EBITDA* | $ | 1,042.3 | D | |||||
|
| |||||||
Fiscal 2008 LTM Adjusted EBITDA | 829.1 | |||||||
“Run Rate” Cost Savings** | 57.0 | |||||||
|
| |||||||
Fiscal 2008 LTM Adjusted EBITDA* | $ | 886.1 | H | |||||
|
| |||||||
Senior Secured Leverage Ratio* | 2.55 | A+B / D | 4.01 | E+F / H | ||||
Total Leverage Ratio* | 5.43 | C / D | 6.97 | G / H | ||||
| * | See Non-GAAP Financial Measures Disclosure |
| ** | As defined by the Credit Agreement dated September 25, 2007 |
Biomet, Inc.
Other Financial Information
Reconciliation of Operating Income (Loss) or Net Loss, as reported to EBITDA, as adjusted*
(in millions, unaudited)
| Three Months Ended May 31, 2012 | Three Months Ended February 29, 2012 | Three Months Ended November 30, 2011 | ||||||||||
Operating Income (Loss), as reported | $ | (378.0 | ) | $ | 108.1 | $ | 103.8 | |||||
Depreciation | 44.2 | 43.9 | 47.3 | |||||||||
Amortization | 77.2 | 82.6 | 84.4 | |||||||||
Special items adjustments | ||||||||||||
Stock-based compensation expense | 3.8 | 3.5 | 4.0 | |||||||||
Litigation settlements and reserves and other legal fees | (12.7 | ) | 12.8 | 7.5 | ||||||||
Trauma acquisition costs | 4.6 | — | — | |||||||||
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) | 6.0 | 6.9 | 16.5 | |||||||||
Sponsor fee | 2.8 | 2.7 | 2.8 | |||||||||
Goodwill and intangible assets impairment charge | 529.8 | — | — | |||||||||
|
|
|
|
|
| |||||||
EBITDA, as adjusted* | $ | 277.7 | $ | 260.5 | $ | 266.3 | ||||||
|
|
|
|
|
| |||||||
| Year Ended May 31, 2008 | ||||
Net loss, as reported | $ | (1,018.8 | ) | |
Depreciation | 140.8 | |||
Amortization | 329.8 | |||
Interest expense | 516.6 | |||
Other (income) expense | 9.1 | |||
Income tax benefit | (257.4 | ) | ||
Additional cost of sales for inventory write up to fair value | 160.2 | |||
In-process research and development | 479.0 | |||
Financing fees related to merger | 171.6 | |||
Share-based payment | 25.8 | |||
In-the-money stock option settlement | 112.8 | |||
Distributor agreements | 41.7 | |||
Department of Justice | 26.9 | |||
Investment banker fee | 29.6 | |||
Consulting expenses related to operational improvement initiatives, severance for former executives, sponsor fees and other related costs | 49.6 | |||
Additional legal/merger related fees | 11.8 | |||
|
| |||
EBITDA, as adjusted* | $ | 829.1 | ||
|
| |||
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Consolidated Statement of Cash Flows
(in millions, unaudited)
| Fiscal 2013 | ||||
| (Preliminary) Three Months Ended August 31, 2012 | ||||
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES: | ||||
Net loss | $ | (31.5 | ) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
Depreciation and amortization | 120.6 | |||
Amortization and write off of deferred financing costs | 7.0 | |||
Stock-based compensation expense | 19.1 | |||
Loss on extinguishment of debt | 38.0 | |||
Provision for doubtful accounts receivable | 1.3 | |||
Deferred income taxes | (68.9 | ) | ||
Other | (1.3 | ) | ||
Changes in operating assets and liabilities, net of acquired assets: | ||||
Accounts receivable | 5.8 | |||
Inventories | (21.2 | ) | ||
Prepaid expenses | (4.2 | ) | ||
Accounts payable | (8.1 | ) | ||
Income taxes | (4.2 | ) | ||
Accrued interest | 51.9 | |||
Accrued expenses and other | (18.8 | ) | ||
|
| |||
Net cash provided by operating activities | 85.5 | |||
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: | ||||
Capital expenditures | (53.1 | ) | ||
Acquisitions, net of cash acquired—Trauma Acquisition | (280.0 | ) | ||
Other acquisitions, net of cash acquired | (5.9 | ) | ||
|
| |||
Net cash used in investing activities | (339.0 | ) | ||
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES: | ||||
Debt: | ||||
Payments under European facilities | (0.4 | ) | ||
Payments under senior secured credit facilities | (8.5 | ) | ||
Proceeds from Senior notes | 1,000.0 | |||
Tender of Senior notes | (581.7 | ) | ||
Payment of fees related to refinancing activities | (30.1 | ) | ||
|
| |||
Net cash provided by financing activities | 379.3 | |||
Effect of exchange rate changes on cash | 1.0 | |||
|
| |||
Increase in cash and cash equivalents | 126.8 | |||
Cash and cash equivalents, beginning of period | 492.4 | |||
|
| |||
Cash and cash equivalents, end of period | $ | 619.2 | ||
|
| |||
Supplemental disclosures of cash flow information: | ||||
Cash paid during the period for: | ||||
Interest | $ | 62.5 | ||
|
| |||
Income taxes | $ | 22.0 | ||
|
| |||
Biomet, Inc.
Consolidated Statement of Cash Flows
(in millions, unaudited)
| Fiscal 2012 | ||||
| Three Months Ended 8/31/2011(1) | ||||
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES: | ||||
Net loss | $ | (39.2 | ) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
Depreciation and amortization | 129.8 | |||
Amortization of deferred financing costs | 2.8 | |||
Stock-based compensation expense | 4.7 | |||
Recovery of doubtful accounts receivable | (2.5 | ) | ||
Loss on impairment of investments | 9.2 | |||
Deferred income taxes | (67.0 | ) | ||
Other | (0.6 | ) | ||
Changes in operating assets and liabilities: | ||||
Accounts receivable | 21.3 | |||
Inventories | (2.7 | ) | ||
Prepaid expenses | 2.7 | |||
Accounts payable | (1.5 | ) | ||
Income taxes | 22.4 | |||
Accrued interest | 67.8 | |||
Accrued expenses and other | (24.1 | ) | ||
|
| |||
Net cash provided by operating activities | 123.1 | |||
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: | ||||
Proceeds from sales/maturities of investments | 33.7 | |||
Purchases of investments | (0.2 | ) | ||
Proceeds from sale of property and equipment | 0.1 | |||
Capital expenditures | (39.2 | ) | ||
Acquisitions, net of cash acquired | (3.9 | ) | ||
|
| |||
Net cash used in investing activities | (9.5 | ) | ||
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES: | ||||
Debt: | ||||
Payments under European facilities | (0.5 | ) | ||
Payments under senior secured credit facilities | (8.9 | ) | ||
Equity: | ||||
Repurchase of LVB Acquisition, Inc. shares | (0.3 | ) | ||
|
| |||
Net cash used in financing activities | (9.7 | ) | ||
Effect of exchange rate changes on cash | (0.5 | ) | ||
|
| |||
Increase in cash and cash equivalents | 103.4 | |||
Cash and cash equivalents, beginning of period | 327.8 | |||
|
| |||
Cash and cash equivalents, end of period | $ | 431.2 | ||
|
| |||
Supplemental disclosures of cash flow information: | ||||
Cash paid during the period for: | ||||
Interest | $ | 55.0 | ||
|
| |||
Income taxes | $ | 20.7 | ||
|
| |||
| (1) | Certain amounts have been adjusted to conform to the current presentation. |
Biomet, Inc.
Other Financial Information
GAAP Operating Cash Flow Reconciled to Free Cash Flow* & Unlevered Free Cash Flow*
(in millions, unaudited)
| Fiscal 2013 | ||||
| (Preliminary) | ||||
| Three Months Ended August 31, 2012 | ||||
Net loss | $ | (31.5 | ) | |
Adjustments: | ||||
Depreciation and amortization | 120.6 | |||
Amortization and write off of deferred financing costs | 7.0 | |||
Stock-based compensation expense | 19.1 | |||
Loss on extinguishment of debt | 38.0 | |||
Provision for doubtful accounts receivable | 1.3 | |||
Deferred income taxes | (68.9 | ) | ||
Other | (1.3 | ) | ||
|
| |||
TOTAL | 84.3 | |||
Changes In: | ||||
Accounts receivable | 5.8 | |||
Inventories | (21.2 | ) | ||
Prepaid expenses | (4.2 | ) | ||
Accounts payable | (8.1 | ) | ||
Income taxes | (4.2 | ) | ||
Accrued interest | 51.9 | |||
Accrued expenses and other | (18.8 | ) | ||
|
| |||
Net cash provided by operating activities | $ | 85.5 | ||
Capital expenditures | (53.1 | ) | ||
|
| |||
Free Cash Flow* | $ | 32.4 | ||
Add back: cash paid for interest | 62.5 | |||
|
| |||
Unlevered Free Cash Flow* (1) | $ | 94.9 | ||
|
| |||
| (1) | Defined as Free Cash Flow plus cash paid for interest. Commonly used by companies that are highly leveraged to show how assets perform before interest payments. |
| * | See Non-GAAP Financial Measures Disclosure |
Biomet, Inc.
Other Financial Information
GAAP Operating Cash Flow Reconciled to Free Cash Flow* & Unlevered Free Cash Flow*
(in millions, unaudited)
| Fiscal 2012 | ||||
| Three Months Ended 8/31/2011(2) | ||||
Net loss | $ | (39.2 | ) | |
Adjustments: | ||||
Depreciation and amortization | 129.8 | |||
Amortization of deferred financing costs | 2.8 | |||
Stock-based compensation expense | 4.7 | |||
Recovery of doubtful accounts receivable | (2.5 | ) | ||
Loss on impairment of investments | 9.2 | |||
Deferred income taxes | (67.0 | ) | ||
Other | (0.6 | ) | ||
|
| |||
TOTAL | 37.2 | |||
Changes In: | ||||
Accounts receivable | 21.3 | |||
Inventories | (2.7 | ) | ||
Prepaid expenses | 2.7 | |||
Accounts payable | (1.5 | ) | ||
Income taxes | 22.4 | |||
Accrued interest | 67.8 | |||
Accrued expenses and other | (24.1 | ) | ||
|
| |||
Net cash provided by operating activities | $ | 123.1 | ||
Capital expenditures | (39.2 | ) | ||
|
| |||
Free Cash Flow* | $ | 83.9 | ||
Add back: cash paid for interest | 55.0 | |||
|
| |||
Unlevered Free Cash Flow* (1) | $ | 138.9 | ||
|
| |||
| (1) | Defined as Free Cash Flow plus cash paid for interest. Commonly used by companies that are highly leveraged to show how assets perform before interest payments. |
| (2) | Certain amounts have been adjusted to conform to the current presentation. |
| * | See Non-GAAP Financial Measures Disclosure |